Kapstone Financial Advisors LLC Has $185,000 Stake in Abrdn Life Sciences Investors (NYSE:HQL)

Kapstone Financial Advisors LLC raised its stake in Abrdn Life Sciences Investors (NYSE:HQL) by 11.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,123 shares of the company’s stock after buying an additional 1,300 shares during the quarter. Kapstone Financial Advisors LLC’s holdings in Abrdn Life Sciences Investors were worth $185,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Stephens Inc. AR lifted its stake in Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after buying an additional 896 shares during the period. Sanctuary Advisors LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after purchasing an additional 1,355 shares in the last quarter. BankPlus Trust Department bought a new position in shares of Abrdn Life Sciences Investors during the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 379.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock valued at $64,000 after purchasing an additional 3,847 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 7.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock valued at $1,199,000 after purchasing an additional 6,200 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Trading Down 1.5 %

NYSE:HQL opened at $13.25 on Tuesday. Abrdn Life Sciences Investors has a fifty-two week low of $12.76 and a fifty-two week high of $15.90. The business’s 50-day simple moving average is $13.73 and its 200-day simple moving average is $14.41.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, February 21st will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 14.19%. The ex-dividend date of this dividend is Friday, February 21st.

Insider Activity

In other news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61. Following the transaction, the insider now owns 3,381,371 shares in the company, valued at $48,252,164.17. The trade was a 0.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 108,386 shares of company stock worth $1,511,590 in the last 90 days. Corporate insiders own 10.06% of the company’s stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.